Table 1 Demographic and clinical characteristics of the patient cohort
TOTAL (N = 174) | SURVIVOR n = 34 (%19.5) | NON-SURVIVOR n = 140 (%80.5) | P | |||
|---|---|---|---|---|---|---|
DEMOGRAHY | Age Median (IQR) | 85 (81-89) | 83 (80.75-86.5) | 86 (82-89) | 0.037 | |
Age | 80-90 | 150 (86.2%) | 31 (91.2%) | 119 (85.0%) | 0.420 | |
> 90 | 24 (13.8%) | 3 (8.8%) | 21 (15.0%) | |||
Sex | Male | 102 (58.6%) | 21 (61.8%) | 81 (57.9%) | 0.678 | |
Female | 72 (41.4%) | 13 (38.2%) | 59 (42.1%) | |||
Length of Stay | 7 (3.75-12) | 7 (4-11.25) | 7 (3-12.75) | 0.976 | ||
COMORBIDITY | DM | 56 (32,2%) | 11 (32.4%) | 45 (32.1%) | 0.981 | |
HT | 100 (57.5%) | 21 (61.8%) | 79 (56.4%) | 0.572 | ||
CAD | 52 (29.9%) | 10 (29.4%) | 42 (30.0%) | 0.946 | ||
COPD | 31 (17.8%) | 8 (23.5%) | 23 (16.4%) | 0.332 | ||
Other | 115 (66.1%) | 19 (55.9%) | 96 (68.6%) | 0.161 | ||
LABORATORY VALUES Median (IQR) | CRP | 120.5 (69-202.25) | 87.5 (35.75-183.25) | 124 (76.25-210.75) | 0.011 | |
PCT | 0.61 (0.23-2.76) | 0.295 (0.13-1.475) | 0.725 (0.28-3.185) | 0.030 | ||
Ferritin | 434 (189-952) | 239 (89.35-491.5) | 568 (232.25-1072.5) | 0.002 | ||
D-Dimer | 1549.5 (868.5-3281.75) | 1280 (824.5-2527) | 1620 (897.5-3407) | 0.274 | ||
Troponin | 7 (0.07-81.6) | 13 (0.23-47.25) | 0.66 (0.065-88) | 0.426 | ||
Lactate | 1.93 (1.4-2.95) | 1.785 (1.23-2.595) | 2.015 (1.425-3.15) | 0.128 | ||
Albumin | 27 (21.9-31.8) | 29.55 (23.6-34.15) | 26.5 (21.5-30.8) | 0.032 | ||
Urea | 76 (55.75-118.5) | 64.5 (50.25-97.5) | 77.5 (59-120.75) | 0.096 | ||
Creatinine | 1.235 (0.86-2.045) | 1 (0.74-1.78) | 1.32 (0.92-2.14) | 0.074 | ||
ALT | 21 (14-35) | 22.5 (13.75-32) | 20.5 (14-35.75) | 0.894 | ||
AST | 38 (25-55) | 32.5 (23.75-43.25) | 40 (25-61) | 0.096 | ||
PaO2 | 78 (60-104) | 84 (59-117.25) | 78 (60-100) | 0.530 | ||
PaCO2 | 36 (28-49.25) | 34.2 (28.75-50) | 37 (28-49) | 0.953 | ||
LDH | 362 (270.5-517.5) | 285 (233.75-486.75) | 381 (292-536) | 0.019 | ||
WBC | 11,140 (7085-15,395) | 10,762 (6927.5-14,017.5) | 11,600 (7150-16,090) | 0.365 | ||
Lymphocyte | 690 (440-1165) | 855 (535-1550) | 660 (420-1130) | 0.078 | ||
TREATMENT | IMV | 141 (81.0%) | 5 (14.7%) | 136 (97.1%) | < 0.001 | |
HFNC and/or NIMV | 33 (19%) | 29 (85.3%) | 4 (2.9%) | |||
HDF | 10 (5.7%) | 4 (11.8%) | 6 (4.3%) | 0.107 | ||
Anti-cytokines | 3 (1.7%) | 1 (2.9%) | 2 (1.4%) | 0.481 | ||
Plasma | 5 (2.9%) | 2 (5.9%) | 3 (2.1%) | 0.252 | ||
COMPUTED TOMOGRAPHY | Non-Infiltration | 32 (18.4%) | 10 (29.4%) | 22 (15.7%) | 0.147 | |
Unilateral Infiltration | 23 (13.2%) | 5 (14.7%) | 18 (12.9%) | |||
Bilateral Infiltration | 119 (68.4%) | 19 (55.9%) | 100 (71.4%) | |||